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■ SHORT COMMUNICATION ■
Introduction
Multiple primary cancer is a rare condition. The concept
of multiple malignant lesions has interested investiga-
tors since 1889, when Billroth first described the condi-
tion [1]. Synchronous and metachronous are terms
used to describe the occurrence of second primary
tumors. Synchronous tumors occur, or are diagnosed, at
the same time; metachronous tumors occur at differ-
ent times. Moore et al introduced the concept of syn-
chronous tumors and defined them as secondary
tumors that occur within 12 months [2]. If a new tumor
develops many years after the first, then the previously
administered radiotherapy or chemotherapy must be
considered to be a possible carcinogen. It is often pos-
tulated that when two tumors occur in close succession,
they may have been exposed to the same hormone or
carcinogen. The most common synchronous gyneco-
logic tumors are ovarian and endometrial; synchronous
ovarian and endocervical tumors have rarely been
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SUMMARY
Objective: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma
and endocervical mucinous adenocarcinoma. Related literature was reviewed and it appeared that no similar
case had been reported previously.
Case Report: A 30-year-old (gravida 1, para 1, abortus 0) woman complained of abdominal fullness, chest
tightness and dyspnea on exertion of several days’ duration. Gynecologic sonography showed a right complex
adnexal cyst, 16 × 14 cm in size. Computed tomography showed an 18 × 16 cm right pelvic tumor, with both
cystic and solid components, ascites and bilateral massive pleural effusion. Cytology of the pleural effusion
showed no malignant cells. The patient underwent staging surgery. Histology showed moderately to poorly dif-
ferentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well
as paraaortic and bilateral pelvic lymph node metastases. Extensive tumor thrombi were observed in the lym-
phovascular channels of the left ovary, bilateral tubes and uterus. Endocervical adenocarcinoma, < 3 mm in
depth, was also identified on the cervix. The final surgical-pathologic stage of ovarian endometrioid adenocar-
cinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1. Adjuvant chemotherapy
with carboplatin and paclitaxel was prescribed postoperatively, but the malignancy was not controlled due to
lung, brain and vulva metastases. The patient died of respiratory failure.
Conclusion: The coexistence of primary neoplasms in the ovary and cervix is rare. Diagnosis should be based on
histologic examination and requires appropriate treatment for both tumors. [Taiwanese J Obstet Gynecol 2006;
45(3):264–267]
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Case Report
A 30-year-old woman (gravida 1, para 1, abortus 0)
with no significant past medical history visited our
outpatient department on January 4, 2005 with the
complaints of chest tightness, dyspnea on exertion and
orthopnea of several days’ duration. She had a non-
tender abdominal mass, increased abdominal girth,
nausea and decreased appetite over the past month.
Gynecologic sonography showed a right complex adnexal
cyst, measuring 16 × 14cm in size, with ascites and bilat-
eral pleural effusion. She was admitted for further
evaluation the same day. Abdominal and pelvic com-
puted tomography (CT) showed a large tumor with
both cystic and solid parts in the pelvis, mainly on the
right side, ascites and massive bilateral pleural effusion
(Figure 1). Cytologic examination of the pleural effusion,
performed twice, showed no malignant cells. The serum
CA-125 level was 702 U/mL but the carcinoembryonic
antigen (CEA) level was within the normal range. The
results of preoperative examinations, including blood,
urine, liver function, renal function, electrolytes, elec-
trocardiogram and chest X-ray, were all within normal
ranges except for bilateral pleural effusion.
The patient underwent laparotomy on January 7,
2005. Yellowish, watery ascites (~1,000 mL) was found
in the abdominal cavity and was sent for cytologic exam-
ination. The cystic mass, 16×14×15 cm, had a dark red
smooth surface with no adhesions to the peritoneum or
intestines. The internal content comprised fragile soft
tissue soaked in a cola-like fluid and a small daughter
cyst containing chocolate-like fluid. Frozen section of 
the right ovary disclosed endometrioid adenocarcinoma
with papillary architecture and massive tumor necrosis.
The left ovary had a rough surface measuring about
4.5 × 4 × 4 cm in size. The internal content was a
chocolate-like fluid. There was no enlargement of the
retroperitoneal lymph nodes. Staging surgery was per-
formed, including total abdominal hysterectomy, bilat-
eral salpingo-oophorectomy, bilateral pelvic lymph
node dissection, paraaortic lymph node sampling, bilat-
eral infundibulopelvic ligament resection, appendec-
tomy and omentectomy.
In the final pathology report, the section of the right
ovary mass showed a picture of grade 2/3 endometri-
oid adenocarcinoma with tumor necrosis, papillary
growth pattern, endometriosis and extensive lympho-
vascular permeation (Figure 2). Metastatic adenocar-
cinoma with tumor thrombus in the lymphovascular
channels was found on the left ovary, bilateral tubes,
uterus, cervix, bilateral pelvic lymph nodes and
paraaortic lymph nodes. The cervix also presented with
metastatic adenocarcinoma, about 18 mm in depth
and 7 mm in width. Interestingly, according to the his-
tochemical studies, endocervical mucinous adenocar-
cinoma was identified on the cervix (Figure 3), which
Figure 1. Computed tomography shows a large pelvic tumor
with cystic and solid parts.
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Figure 2. (A) Ovarian endometrioid adenocarcinoma: complex, branching glands with focal tumor necrosis; glandular lesion
showing irregular budding but smooth surface; tall columnar cells with central nuclei and nuclear stratification (hematoxylin
& eosin, 100×). (B) Tumor cell nonreactive to carcinoembryonic antigen (CEA).
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was reactive for CEA and nonreactive for vimentin. The
lesion was < 3 mm in depth. The tumor on the ovary
was negative for CEA and vimentin. The cytology of the
ascites was negative for malignancy. The final surgical-
pathologic stage of ovarian endometrioid adenocarci-
noma was stage IIIc and of endocervical mucinous
adenocarcinoma was stage IA1.
After surgery, adjuvant chemotherapy with carbopla-
tin (area under the curve, 5) and paclitaxel (175 mg/m2)
was prescribed monthly from January 14, 2005.
Although CA-125 serum level declined to within the
normal range, multiple nodules in both lungs, prevas-
cular and pretracheal spaces were present on CT 2
months later. Gemcitabine 800 mg/m2 was added. How-
ever, tiny nodules were apparent on chest X-ray, when
compared to previous X-rays, and the CA-125 level 
was slightly elevated from 9.06 U/mL to 43.7 U/mL.
After finishing six courses of adjuvant chemotherapy,
18F-2-fluoro-2-deoxy-D-glucose positron emission tomo-
graphy (FDG-PET) was arranged and disclosed increas-
ing FDG uptake in both lungs, liver, paraaortic region
and pelvis, compatible with multiple metastases. Sal-
vage chemotherapy with pegylated doxorubicin HCl 
liposome was continued but progressive dyspnea and
cachexia developed. She was transferred to a hospice
ward on August 8, 2005 and died of respiratory failure
on September 1, 2005.
Discussion
In 1961, Moertel et al described 1,909 patients who were
found to have multiple primary malignant neoplasms out
of 37,580 patients with malignant neoplasms in a 10-
year period, which represented an overall occurrence rate
of 4.6% [3]. They also reported six cases of cervical and
ovarian cancer among 921 cases of double primary
tumors derived from multiple tissues of origin, although
they were not divided into synchronous or metachro-
nous [3]. In 1984, the occurrence rate of synchronous
gynecologic malignancies in patients with gynecologic
tumors was 1.78%, and three cases of synchronous
invasive cervical cancer and ovarian tumor were found
among 2,362 patients by Axelrod et al in the Downstate
Medical Center Tumor Registry [4]. In 1989, Eisner et al
reviewed the histopathology of 3,863 patients with
female genital malignancies in the UCLA Tumor Registry
over a 30-year period [5]. Twenty-six patients (0.7%)
with invasive synchronous primary cancers were identi-
fied. The most frequent synchronous genital lesions were
ovarian and endometrial cancer in 11 patients (0.3%),
with only a single case of synchronous ovarian and cer-
vical tumors (0.025%) [5]. In 1983, LiVolsi reported
four cases of endocervical adenocarcinoma coexisting
with ovarian mucinous adenocarcinoma [6]. In 2004,
two cases of synchronous ovarian and cervical cancer
were reported out of 861 women with gynecologic
tumors in Taiwan [7]. One of the cervical cancers was
squamous cell carcinoma and the other was adenosqua-
mous carcinoma. The ovarian cancers were both serous
cystadenocarcinoma [7].
Our patient presented with rare synchronous pri-
mary gynecologic tumors of ovarian endometrioid and
endocervical mucinous adenocarcinomas. Distinction
between endometrial and endocervical adenocarcino-
mas may be made by using a small panel of antibodies,
including CEA, estrogen receptor and vimentin [8].
Cells containing CEA are detected in approximately
80% of endocervical adenocarcinoma and < 10% of
endometrial carcinomas [9]. The cervical tumor in this
case had diffuse positivity to CEA and the ovarian
tumor cells were nonreactive to CEA (Figures 2B and 3B).
Recently, human papillomavirus (HPV) DNA was
assessed to determine whether ovarian neoplasms were
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Figure 3. (A) Cervical endocervical mucinous adenocarcinoma: tumor in the endocervical canal, about 3 mm in depth;
glands with tall columnar cells containing basal nuclei and apical intracytoplasmic mucin; no focal adenocarcinoma found in
situ (not shown here) (hematoxylin & eosin, 100×). (B) Diffuse positivity to carcinoembryonic antigen (CEA) (black arrows).
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metastatic or independent. The presence of HPV DNA
in ovarian tumors confirms that they are metastatic
endocervical adenocarcinomas [10].
Ovarian endometrioid carcinoma was reported to
have the highest incidence of multiple primary tumors
(21.3%) in 413 patients with primary ovarian tumors in
Silverman et al’s study [11]. Embryologic, hormonal,
genetic or other phenomena may be associated with the
development of malignancies arising simultaneously in
genital tissues [11–13]. Ovarian and endometrial can-
cers are the most common synchronous primary tumors.
Generally, synchronous double primary cancers have 
a more favorable prognosis than a tumor of a single
metastatic lesion [7]. Patients with low stage and low
grade synchronous ovarian and endometrial cancers have
excellent prognoses. Detection at a relatively early stage
suggests diagnosis may be facilitated by early symptoms
from the endometrial carcinoma [5]. Our patient had
an advanced stage of ovarian cancer when diagnosed.
In this case, the reaction or nonreaction of immuno-
histochemical stain to CEA on the tissue slides deter-
mined the ovarian tumor cells from the endocervical
ones. The treatment plan was mainly based on the
protocol for advanced ovarian cancer since hysterec-
tomy is adequate treatment for cervical lesions.
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